Yongsu Zhen Selected Research

IMB5043

1/2018

A new compound of thiophenylated pyridazinone IMB5043 showing potent antitumor efficacy through ATM-Chk2 pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yongsu Zhen Research Topics

Disease

18	Neoplasms (Cancer) 12/2022 - 03/2002
4	Necrosis 01/2018 - 03/2006
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2018
3	Lymphoma (Lymphomas) 01/2019 - 01/2016
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 01/2016
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016 - 03/2011
2	Carcinoma (Carcinomatosis) 09/2010 - 10/2009
1	Esophageal Neoplasms (Esophageal Cancer) 12/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2019
1	Breast Neoplasms (Breast Cancer) 12/2017
1	Colonic Neoplasms (Colon Cancer) 05/2016
1	Multiple Myeloma 01/2016
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2016
1	Leukemia 01/2015
1	Hepatocellular Carcinoma (Hepatoma) 01/2015
1	Body Weight (Weight, Body) 04/2012
1	Psoriatic Arthritis 09/2007
1	Experimental Arthritis 09/2007
1	Inflammation (Inflammations) 09/2007
1	Rheumatoid Arthritis 09/2007
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2007
1	Arthritis (Polyarthritis) 09/2007
1	Neoplasm Metastasis (Metastasis) 01/2004

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 12/2022 - 10/2009
8	C 1027IBA 12/2022 - 09/2010
6	Pharmaceutical PreparationsIBA 12/2022 - 01/2015
5	Immunoconjugates (Immunoconjugate)IBA 12/2022 - 03/2002
4	ApoproteinsIBA 12/2022 - 10/2009
3	Single-Chain AntibodiesIBA 04/2012 - 03/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2008 - 03/2006
2	ErbB Receptors (EGF Receptor)IBA 12/2022 - 04/2012
2	AlbuminsIBA 01/2020 - 01/2018
2	Recombinant ProteinsIBA 01/2020 - 01/2018
2	GelatinasesIBA 01/2018 - 09/2010
2	Immunoglobulin FragmentsIBA 12/2017 - 04/2012
1	Recombinant Fusion ProteinsIBA 12/2022
1	Inosine Monophosphate (IMP)IBA 12/2022
1	Human Serum Albumin FDA LinkGeneric 12/2022
1	Oxidoreductases (Dehydrogenase)IBA 12/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	mithramycin AIBA 01/2022
1	Plicamycin FDA Link 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Anaplastic Lymphoma KinaseIBA 01/2019
1	CrizotinibIBA 01/2019
1	Arginine (L-Arginine)FDA Link 01/2018
1	IMB5043IBA 01/2018
1	Cell-Penetrating PeptidesIBA 01/2018
1	NGR peptideIBA 12/2017
1	Histone Deacetylases (Histone Deacetylase)IBA 05/2016
1	cinnamic acidIBA 05/2016
1	Rituximab (Mabthera)FDA Link 01/2016
1	CateninsIBA 01/2015
1	CD20 AntigensIBA 03/2011
1	OligopeptidesIBA 10/2009
1	LigandsIBA 10/2009
1	Biological ProductsIBA 10/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2009
1	CytokinesIBA 09/2007
1	Collagen Type II (Type II Collagen)IBA 09/2007
1	Therapeutic UsesIBA 09/2007
1	triethylammonium bicarbonateIBA 09/2007
1	caffeic acidIBA 01/2004
1	Immunoglobulin Fab FragmentsIBA 03/2002
1	AntigensIBA 03/2002
1	Monoclonal AntibodiesIBA 03/2002

Therapy/Procedure

10	Therapeutics 12/2022 - 09/2007
1	Drug Therapy (Chemotherapy) 01/2019
1	Transplantation 03/2011